Tbio ANK1 Ankyrin-1

Protein Summary

Description

Attaches integral membrane proteins to cytoskeletal elements; binds to the erythrocyte membrane protein band 4.2, to Na-K ATPase, to the lymphocyte membrane protein GP85, and to the cytoskeletal proteins fodrin, tubulin, vimentin and desmin. Erythrocyte ankyrins also link spectrin (beta chain) to the cytoplasmic domain of the erythrocytes anion exchange protein; they retain most or all of these binding functions. Isoform Mu17 together with obscurin in skeletal muscle may provide a molecular link between the sarcoplasmic reticulum and myofibrils. Ankyrins are a family of proteins that link the integral membrane proteins to the underlying spectrin-actin cytoskeleton and play key roles in activities such as cell motility, activation, proliferation, contact and the maintenance of specialized membrane domains. Multiple isoforms of ankyrin with different affinities for various target proteins are expressed in a tissue-specific, developmentally regulated manner. Most ankyrins are typically composed of three structural domains: an amino-terminal domain containing multiple ankyrin repeats; a central region with a highly conserved spectrin binding domain; and a carboxy-terminal regulatory domain which is the least conserved and subject to variation. Ankyrin 1, the prototype of this family, was first discovered in the erythrocytes, but since has also been found in brain and muscles. Mutations in erythrocytic ankyrin 1 have been associated in approximately half of all patients with hereditary spherocytosis. Complex patterns of alternative splicing in the regulatory domain, giving rise to different isoforms of ankyrin 1 have been described. Truncated muscle-specific isoforms of ankyrin 1 resulting from usage of an alternate promoter have also been identified. [provided by RefSeq, Dec 2008]

Uniprot Accession IDs

• P16157
• A0PJN8
• A6NJ23
• E5RFL7
• O43400
• Q13768
• Q53ER1
• Q59FP2
• Q8N604
• Q99407
• ANK-1

Gene Name

• ANK1

Ensembl ID

• ENST00000265709
• ENSP00000265709
• ENSG00000029534
• ENST00000289734
• ENSP00000289734
• ENST00000314214
• ENSP00000319123
• ENST00000347528
• ENSP00000339620
• ENST00000348036
• ENSP00000297744
• ENST00000522543
• ENSP00000430368

Symbol

• ANK
• ANK
• SPH1
• SPH2

Knowledge Table

Most Knowledge About	Knowledge Value (0 to 1 scale)
cellular component	1
trait	1
disease perturbation	0.93
transcription factor perturbation	0.88
disease	0.81

IDG Development Level Summary

Tdark

These are targets about which virtually nothing is known. They do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:

Pubmed score: 309.99   (req: < 5)

Gene RIFs: 43   (req: <= 3)

Antibodies: 363   (req: <= 50)

Tbio

These targets do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:

Pubmed score: 309.99   (req: >= 5)

Gene RIFs: 43   (req: > 3)

Antibodies: 363   (req: > 50)

- OR - satisfy the following criterion:

Gene Ontology Terms: 15

Tchem

Target has at least one ChEMBL compound with an activity cutoff of < 30 nM - AND - satisfies the preceding conditions

Active Ligand: 0

Tclin

Target has at least one approved drug - AND - satisfies the preceding conditions

Active Drug: 0

Protein Data Bank (8)

1 – 5 of 8

PDB Structure Id	Ligand	Method	Resolution (Å)	M.W. (kDa)	Pub Year	Title

PDB Structure Id	M.W.	Resolution	Pub Year

Pathways (16)

Reactome (15)

KEGG (1)

Asparagine N-linked glycosylation (R-HSA-446203)

Click on a row in the table to change the structure displayed.

Items per page:

5

1 – 5 of 15

Data Source	Name	Explore in Pharos	Explore in Source
Reactome	Asparagine N-linked glycosylation	286 targets	R-HSA-446203
Reactome	Axon guidance	533 targets	R-HSA-422475
Reactome	CHL1 interactions	9 targets	R-HSA-447041
Reactome	COPI-mediated anterograde transport	83 targets	R-HSA-6807878
Reactome	Developmental Biology	1055 targets	R-HSA-1266738

Name	Explore in Pharos	Explore in Source
Asparagine N-linked glycosylation	286 targets	R-HSA-446203
Axon guidance	533 targets	R-HSA-422475
CHL1 interactions	9 targets	R-HSA-447041
COPI-mediated anterograde transport	83 targets	R-HSA-6807878
Developmental Biology	1055 targets	R-HSA-1266738

Gene Ontology Terms (30)

Functions (8)

Components (15)

Processes (7)

Items per page:

10

1 – 8 of 8

GO Term	Evidence	Assigned by
cytoskeletal adaptor activity	Inferred from Direct Assay (IDA)	BHF-UCL
spectrin binding	Inferred from Direct Assay (IDA)	ARUK-UCL
ATPase binding	Inferred from Physical Interaction (IPI)	BHF-UCL
enzyme binding	Inferred from Physical Interaction (IPI)	UniProtKB
protein phosphatase binding	Inferred from Physical Interaction (IPI)	ARUK-UCL
ion channel binding	Inferred from Biological aspect of Ancestor (IBA)	GO_Central
structural constituent of cytoskeleton	Traceable Author Statement (TAS)	ProtInc
structural molecule activity	Non-traceable Author Statement (NAS)	UniProtKB

Protein-Protein Interactions (167)

Explore Interacting Targets

1 – 10 of 167

• See Interactions on String-DB

RAPGEF5

Tbio

Novelty: 0.02176235

p_int: 0.999999879

p_ni: 1.03e-7

p_wrong: 1.8e-8

Score: 0.259

Data Source: BioPlex,STRINGDB

CHL1

Tbio

Novelty: 0.0005177

p_int: 0.999998813

p_ni: 0.000001187

Score: 0.942

Data Source: BioPlex,Reactome,STRINGDB

FIG4

Tbio

Family: Enzyme

Novelty: 0.0038385

p_int: 0.999959465

p_ni: 0.000040524

p_wrong: 1.1e-8

Score: 0.842

Data Source: BioPlex,STRINGDB

PIKFYVE

Tchem

Family: Kinase

Novelty: 0.00543103

p_int: 0.999957701

p_ni: 0.000042299

Score: 0.867

Data Source: BioPlex,STRINGDB

PPP1R12B

Tbio

Family: Enzyme

Novelty: 0.06135268

p_int: 0.999761219

p_ni: 0.000087032

p_wrong: 0.000151749

Data Source: BioPlex

MB

Tbio

Novelty: 0.0001088

p_int: 0.995671066

p_ni: 0.003466394

p_wrong: 0.000862541

Score: 0.265

Data Source: BioPlex,STRINGDB

PDS5B

Tbio

Novelty: 0.00263816

p_int: 0.993672137

p_ni: 0.006327851

p_wrong: 1.2e-8

Score: 0.194

Data Source: BioPlex,STRINGDB

VAC14

Tbio

Novelty: 0.03692957

p_int: 0.978973006

p_ni: 0.021026994

Score: 0.768

Data Source: BioPlex,STRINGDB

NELFB

Tbio

Novelty: 0.07360458

p_int: 0.932192192

p_ni: 0.067047519

p_wrong: 0.000760289

Score: 0.224

Data Source: BioPlex,STRINGDB

ITGAM

Tbio

Novelty: 0.0002405

Score: 0.999

Data Source: STRINGDB

Publication Statistics

PubMed Score  309.99

PubMed score by year

Reset Zoom

PubTator Score  265.45

PubTator score by year

Reset Zoom

Amino Acid Sequence

Residue Counts

Sequence

MPYSVGFREADAATSFLRAARSGNLDKALDHLRNGVDINTCNQNGLNGLHLASKEGHVKMVVELLHKEII

1-70

LETTTKKGNTALHIAALAGQDEVVRELVNYGANVNAQSQKGFTPLYMAAQENHLEVVKFLLENGANQNVA

70-140

TEDGFTPLAVALQQGHENVVAHLINYGTKGKVRLPALHIAARNDDTRTAAVLLQNDPNPDVLSKTGFTPL

140-210

HIAAHYENLNVAQLLLNRGASVNFTPQNGITPLHIASRRGNVIMVRLLLDRGAQIETKTKDELTPLHCAA

210-280

RNGHVRISEILLDHGAPIQAKTKNGLSPIHMAAQGDHLDCVRLLLQYDAEIDDITLDHLTPLHVAAHCGH

280-350

HRVAKVLLDKGAKPNSRALNGFTPLHIACKKNHVRVMELLLKTGASIDAVTESGLTPLHVASFMGHLPIV

350-420

KNLLQRGASPNVSNVKVETPLHMAARAGHTEVAKYLLQNKAKVNAKAKDDQTPLHCAARIGHTNMVKLLL

420-490

ENNANPNLATTAGHTPLHIAAREGHVETVLALLEKEASQACMTKKGFTPLHVAAKYGKVRVAELLLERDA

490-560

HPNAAGKNGLTPLHVAVHHNNLDIVKLLLPRGGSPHSPAWNGYTPLHIAAKQNQVEVARSLLQYGGSANA

560-630

ESVQGVTPLHLAAQEGHAEMVALLLSKQANGNLGNKSGLTPLHLVAQEGHVPVADVLIKHGVMVDATTRM

630-700

GYTPLHVASHYGNIKLVKFLLQHQADVNAKTKLGYSPLHQAAQQGHTDIVTLLLKNGASPNEVSSDGTTP

700-770

LAIAKRLGYISVTDVLKVVTDETSFVLVSDKHRMSFPETVDEILDVSEDEGEELISFKAERRDSRDVDEE

770-840

KELLDFVPKLDQVVESPAIPRIPCAMPETVVIRSEEQEQASKEYDEDSLIPSSPATETSDNISPVASPVH

840-910

TGFLVSFMVDARGGSMRGSRHNGLRVVIPPRTCAAPTRITCRLVKPQKLSTPPPLAEEEGLASRIIALGP

910-980

TGAQFLSPVIVEIPHFASHGRGDRELVVLRSENGSVWKEHRSRYGESYLDQILNGMDEELGSLEELEKKR

980-1050

VCRIITTDFPLYFVIMSRLCQDYDTIGPEGGSLKSKLVPLVQATFPENAVTKRVKLALQAQPVPDELVTK

1050-1120

LLGNQATFSPIVTVEPRRRKFHRPIGLRIPLPPSWTDNPRDSGEGDTTSLRLLCSVIGGTDQAQWEDITG

1120-1190

TTKLVYANECANFTTNVSARFWLSDCPRTAEAVNFATLLYKELTAVPYMAKFVIFAKMNDPREGRLRCYC

1190-1260

MTDDKVDKTLEQHENFVEVARSRDIEVLEGMSLFAELSGNLVPVKKAAQQRSFHFQSFRENRLAMPVKVR

1260-1330

DSSREPGGSLSFLRKAMKYEDTQHILCHLNITMPPCAKGSGAEDRRRTPTPLALRYSILSESTPGSLSGT

1330-1400

EQAEMKMAVISEHLGLSWAELARELQFSVEDINRIRVENPNSLLEQSVALLNLWVIREGQNANMENLYTA

1400-1470

LQSIDRGEIVNMLEGSGRQSRNLKPDRRHTDRDYSLSPSQMNGYSSLQDELLSPASLGCALSSPLRADQY

1470-1540

WNEVAVLDAIPLAATEHDTMLEMSDMQVWSAGLTPSLVTAEDSSLECSKAEDSDATGHEWKLEGALSEEP

1540-1610

RGPELGSLELVEDDTVDSDATNGLIDLLEQEEGQRSEEKLPGSKRQDDATGAGQDSENEVSLVSGHQRGQ

1610-1680

ARITHSPTVSQVTERSQDRLQDWDADGSIVSYLQDAAQGSWQEEVTQGPHSFQGTSTMTEGLEPGGSQEY

1680-1750

EKVLVSVSEHTWTEQPEAESSQADRDRRQQGQEEQVQEAKNTFTQVVQGNEFQNIPGEQVTEEQFTDEQG

1750-1820

NIVTKKIIRKVVRQIDLSSADAAQEHEEVTVEGPLEDPSELEVDIDYFMKHSKDHTSTPNP

1820-1881

MPYSVGFREADAATSFLRAARSGNLDKALDHLRNGVDINTCNQNGLNGLHLASKEGHVKMVVELLHKEIILETTTKKGNTALHIAALAGQDEVVRELVNYGANVNAQSQKGFTPLYMAAQENHLEVVKFLLENGANQNVATEDGFTPLAVALQQGHENVVAHLINYGTKGKVRLPALHIAARNDDTRTAAVLLQNDPNPDVLSKTGFTPLHIAAHYENLNVAQLLLNRGASVNFTPQNGITPLHIASRRGNVIMVRLLLDRGAQIETKTKDELTPLHCAARNGHVRISEILLDHGAPIQAKTKNGLSPIHMAAQGDHLDCVRLLLQYDAEIDDITLDHLTPLHVAAHCGHHRVAKVLLDKGAKPNSRALNGFTPLHIACKKNHVRVMELLLKTGASIDAVTESGLTPLHVASFMGHLPIVKNLLQRGASPNVSNVKVETPLHMAARAGHTEVAKYLLQNKAKVNAKAKDDQTPLHCAARIGHTNMVKLLLENNANPNLATTAGHTPLHIAAREGHVETVLALLEKEASQACMTKKGFTPLHVAAKYGKVRVAELLLERDAHPNAAGKNGLTPLHVAVHHNNLDIVKLLLPRGGSPHSPAWNGYTPLHIAAKQNQVEVARSLLQYGGSANAESVQGVTPLHLAAQEGHAEMVALLLSKQANGNLGNKSGLTPLHLVAQEGHVPVADVLIKHGVMVDATTRMGYTPLHVASHYGNIKLVKFLLQHQADVNAKTKLGYSPLHQAAQQGHTDIVTLLLKNGASPNEVSSDGTTPLAIAKRLGYISVTDVLKVVTDETSFVLVSDKHRMSFPETVDEILDVSEDEGEELISFKAERRDSRDVDEEKELLDFVPKLDQVVESPAIPRIPCAMPETVVIRSEEQEQASKEYDEDSLIPSSPATETSDNISPVASPVHTGFLVSFMVDARGGSMRGSRHNGLRVVIPPRTCAAPTRITCRLVKPQKLSTPPPLAEEEGLASRIIALGPTGAQFLSPVIVEIPHFASHGRGDRELVVLRSENGSVWKEHRSRYGESYLDQILNGMDEELGSLEELEKKRVCRIITTDFPLYFVIMSRLCQDYDTIGPEGGSLKSKLVPLVQATFPENAVTKRVKLALQAQPVPDELVTKLLGNQATFSPIVTVEPRRRKFHRPIGLRIPLPPSWTDNPRDSGEGDTTSLRLLCSVIGGTDQAQWEDITGTTKLVYANECANFTTNVSARFWLSDCPRTAEAVNFATLLYKELTAVPYMAKFVIFAKMNDPREGRLRCYCMTDDKVDKTLEQHENFVEVARSRDIEVLEGMSLFAELSGNLVPVKKAAQQRSFHFQSFRENRLAMPVKVRDSSREPGGSLSFLRKAMKYEDTQHILCHLNITMPPCAKGSGAEDRRRTPTPLALRYSILSESTPGSLSGTEQAEMKMAVISEHLGLSWAELARELQFSVEDINRIRVENPNSLLEQSVALLNLWVIREGQNANMENLYTALQSIDRGEIVNMLEGSGRQSRNLKPDRRHTDRDYSLSPSQMNGYSSLQDELLSPASLGCALSSPLRADQYWNEVAVLDAIPLAATEHDTMLEMSDMQVWSAGLTPSLVTAEDSSLECSKAEDSDATGHEWKLEGALSEEPRGPELGSLELVEDDTVDSDATNGLIDLLEQEEGQRSEEKLPGSKRQDDATGAGQDSENEVSLVSGHQRGQARITHSPTVSQVTERSQDRLQDWDADGSIVSYLQDAAQGSWQEEVTQGPHSFQGTSTMTEGLEPGGSQEYEKVLVSVSEHTWTEQPEAESSQADRDRRQQGQEEQVQEAKNTFTQVVQGNEFQNIPGEQVTEEQFTDEQGNIVTKKIIRKVVRQIDLSSADAAQEHEEVTVEGPLEDPSELEVDIDYFMKHSKDHTSTPNP

Find similar targets by:

Uniprot Keyword

3D-structure
Alternative promoter usage
Alternative splicing
ANK repeat
Complete proteome
Cytoplasm
Cytoskeleton
Direct protein sequencing
Disease mutation
Elliptocytosis